Free Trial
OTCMKTS:KYKOF

Kyowa Kirin (KYKOF) Stock Price, News & Analysis

Kyowa Kirin logo
$16.75 0.00 (0.00%)
(As of 11/21/2024 ET)

About Kyowa Kirin Stock (OTCMKTS:KYKOF)

Key Stats

Today's Range
$16.75
$16.75
50-Day Range
$16.68
$20.97
52-Week Range
$15.78
$22.21
Volume
N/A
Average Volume
2,456 shs
Market Capitalization
N/A
P/E Ratio
0.49
Dividend Yield
119.06%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Kyowa Kirin Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
7th Percentile Overall Score

KYKOF MarketRank™: 

Kyowa Kirin scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Kyowa Kirin.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kyowa Kirin is 0.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kyowa Kirin is 0.49, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.18.

  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Kyowa Kirin has a short interest ratio ("days to cover") of 164.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Kyowa Kirin has recently increased by 21.45%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Kyowa Kirin pays a meaningful dividend of 1.56%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Kyowa Kirin does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Kyowa Kirin is 58.08%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Kyowa Kirin's dividend.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Kyowa Kirin has a short interest ratio ("days to cover") of 164.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Kyowa Kirin has recently increased by 21.45%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Kyowa Kirin has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Kyowa Kirin this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Kyowa Kirin insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 10.28% of the stock of Kyowa Kirin is held by institutions.

  • Read more about Kyowa Kirin's insider trading history.
Receive KYKOF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kyowa Kirin and its competitors with MarketBeat's FREE daily newsletter.

KYKOF Stock News Headlines

This Bull Market Indicator called NVDA at $116
Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…
Kura Oncology, Kyowa Kirin to develop and commercialize ziftomenib in leukemias
See More Headlines

KYKOF Stock Analysis - Frequently Asked Questions

Kyowa Kirin's stock was trading at $16.75 at the start of the year. Since then, KYKOF stock has decreased by 0.0% and is now trading at $16.7472.
View the best growth stocks for 2024 here
.

Shares of KYKOF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
OTCMKTS:KYKOF
CIK
N/A
Fax
N/A
Employees
5,974
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (OTCMKTS:KYKOF) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners